The aHUS trial scene is very active but aHUS patients are often unaware of what is happening. The aHUS alliance will therefore be keeping a watch and periodically report on current trials relating to aHUS ,both Primary and Secondary, to improve awareness.
As at the end of May 2017 the following trials are about to be active or are already recruiting , albeit there may be limitations on who may participate.
Click on each link to learn more the trials.
|OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
|Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
|Not yet recruiting
|Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
|Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
|Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS (STOPECU)
|Enrolling by invitation
|Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment (EVIDENCE)
|Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
|Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients – ECULISHU